MPM Capital, a life-sciences venture capital firm investing in early-stage therapeutics companies, has appointed Matthew Roden PhD, as an Executive Partner. Roden will be responsible for identifying and assessing new technologies and advising portfolio executives on both business and clinical strategies.
Roden brings deep and broad biopharmaceutical experience in both operating and investing arenas. Matt joins MPM from Bristol Myers Squibb, where he held senior leadership roles in strategy and business development. Earlier in his career, Renod was a biotechnology equity research analyst, leading the global team at UBS, and was a senior biotech analyst and associate at JP Morgan.
“Matt’s experience and success as a biopharmaceutical executive, a biotech equity research analyst, and a scientist bring a trifecta of unique and valuable insight to our investment team and the MPM portfolio,” says Ansbert Gadicke, co-founder and managing director, MPM Capital. “We strive to bring the best people with the best experience into the MPM ecosystem. Our goal is to rival the expertise found on the senior teams of vertically integrated pharmaceutical companies so that our portfolio companies have in-house access to the deep knowledge and quality networks across every major step of company building and drug development. We are thrilled to have Matt on the MPM team.”
“MPM’s portfolio has yielded an extraordinary number of approved medicines, which underscores its differentiated capabilities of translating innovative science into novel therapies to reverse life-threatening diseases,” says Roden. “I’m excited to work with the talented team and brilliant scientists in building the next wave of biotech companies with the potential to transform patients’ lives.”
